Instituto de Investigación Sanitaria Galicia Sur (IISGS)
Centro de investigación
Esteban
Daudén Tello
Publicacións nas que colabora con Esteban Daudén Tello (35)
2023
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345
-
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
International Journal of Dermatology
-
The DERMACLEAR study: Verification results of a natural language processing system in dermatology
JEADV Clinical Practice, Vol. 2, Núm. 4, pp. 775-785
2022
-
Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry
British Journal of Dermatology
-
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406
-
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry
Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117
2021
-
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Acta dermato-venereologica, Vol. 101, Núm. 1, pp. adv00354
-
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis
Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517
2020
-
Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 111, Núm. 9, pp. 752-760
-
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150
-
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study
Dermatologic Therapy, Vol. 33, Núm. 6
2019
-
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465
-
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population
British Journal of Dermatology
2018
-
Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study
Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800
-
IL17RA gene variants and anti-TNF response among psoriasis patients
Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 76-80
2017
-
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708
-
Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: Evidence from the psonet registries
Acta Dermato-Venereologica
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts
British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649